Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen

Author(s): U. Elsasser-Beile, P. Buhler, P. Wolf.

Journal Name: Current Drug Targets

Volume 10 , Issue 2 , 2009

Become EABM
Become Reviewer


Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and firstgeneration products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.

Keywords: Prostate specific membrane antigen, prostate cancer, immunotherapy, drug targeting, radiotherapy, gene therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [118 - 125]
Pages: 8
DOI: 10.2174/138945009787354601
Price: $65

Article Metrics

PDF: 13